Children With HIV at Higher Risk of Drug
TUESDAY, April 19 (HealthDay News) -- About 1 in 8 children
infected with HIV experiences triple-class virological failure --
meaning the virus becomes resistant to multiple drugs -- within
five years of starting antiretroviral treatment, a European study
That drug failure rate is higher than in adults and highlights
the challenge of maintaining viral load suppression in young
patients who begin antiretroviral therapy so early in life, the
Virological failure occurs when drugs can no longer reduce the
amount of HIV in a patient's blood, according to the U.S. National
Institutes of Health.
The study included more than 1,000 HIV-positive children in
several European countries. The children, who were infected with
HIV via their mother before or at birth, were under 16 years of age
and began treatment with three or more drugs between 1998 and
Along with an overall 12 percent rate of triple-class
virological failure, the researchers also found that children who
began antiretroviral treatment at an older age were more likely to
One expert said that the higher rate of virological failure may
be tied to lower rates of drug adherence by kids.
"HIV is a dynamic infection in which billions of virus particles are produced each day in the bodies of HIV infected persons," explained Dr. Bruce Hirsch, attending physician in Infectious Disease at North Shore University Hospital in Manhasset, N.Y. "Though each particular virus dies off in less than a day, the high rate of production and the high mutation rate requires that three active anti-viral medicines be present in the blood stream continuously for years."
"Growing up is hard to do," Hirsch added, and "taking unpalatable medications every day is hard on young kids."
But there are potential solutions.
"Easier to take combinations, better tasting syrup versions would help children cope with this infection," Hirsch said.
The study's authors agreed. "There is continued need for
strategies to promote optimum drug adherence in children,
caregivers and young people to minimize the likelihood of
triple-class virological failure, and for development of suitable
new drugs and formulations to optimize the treatment of children
with treatment failure," wrote Ali Judd and colleagues at the
Medical Research Council Clinical Trials Unit in London.
The study appears online April 19 in
The New Mexico AIDS Education and Training Center has more about
HIV and children.
Copyright © 2011
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.